Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Ron Davis speaks about ME / CFS at UT Dallas

It’s #OMFScienceWednesday! Last week, Dr. Ron Davis, our Scientific Advisory Board Director and Director of the Stanford Genome Technology Center, was invited to the University of Texas at Dallas, to speak in their Green Systems Biology Distinguished Lecture Series. He used the opportunity to introduce ME / CFS to approximately 300 biology and bioengineering researchers at UT Dallas, and to present the many technologies being developed at SGTC in the context of their application to ME / CFS. The audience was amazed by what they learned about the disease.

Dr. Davis’ introductory remarks about ME / CFS were interrupted by a professor asking, “Isn’t this a very rare disease?” He responded by pointing out that ME / CFS is more common than Parkinson’s Disease, multiple sclerosis, and AIDS – making it a major disease. The audience’s reaction was shock, prompting another interruption: “How can a disease this common not be widely known?”

After bringing the audience up to speed on the unfortunate reasons that ME / CFS is not more widely known and researched, Dr. Davis presented the OMF-funded research his lab is doing to develop better understanding, diagnosis, and treatment of ME / CFS using cutting-edge technologies. The audience was so intrigued that they stayed for another hour to ask questions, and Dr. Davis didn’t see anyone leave. (This is extremely uncommon for a research seminar, especially one late in the afternoon!) They were amazed at the frequency and severity of the disease, and fascinated by the nature of the research – perhaps what’s most promising is that some asked how they could get started on researching ME / CFS.

We are grateful to Dr. Michael Zhang, Professor and Director of the Center for Systems Biology at UT Dallas, for inviting Dr. Davis to present this lecture. We are hopeful that Dr. Davis’ lecture and similar efforts will continue to spread awareness of ME / CFS in the research and medical communities, and encourage more brilliant minds to study this very important disease. Dr. Davis is definitely eager to give more talks of this nature! #EndMECFS

[envira-gallery id=”9928″]

Read more about Dr. Davis’ talk and similar efforts to increase awareness: www.healthrising.org/forums/threads/ron-davis-talks-on-me-cfs-and-texas-listens.5823/

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.


In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.


The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.


About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.


Heather Ah San

Development and Communications Manager